Takeda and NsGene partner on cell therapies for Parkinson's disease

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) and privately-held NsGene have signed a research agreement to develop encapsulated cell therapies for the potential treatment of Parkinson’s disease.

The partnership will focus on the delivery of recombinant Glial Cell Line-Derived Neurotrophic Factor (GDNF) to affected brain regions by way of implanted, encapsulated cell therapy devices.

NsGene has developed the experimental technology that originated at Brown University into a clinically applicable cell therapy platform. The device contains genetically engineered cells encased in an immune-shielding capsule that can continuously produce therapeutic levels of biotherapeutics for an extended time after implantation. GDNF is a neurotrophic factor that has been shown in preclinical systems to promote axon growth and protect dopaminergic neurons when delivered directly to the diseased cells for an extended duration.

Terms of the deal

NsGene will receive funding from Takeda for technology development that enables NsGene to complete critical scientific milestones needed for clinical trials and further constructive partnering. Further details of the agreement were not disclosed.

Takeda is considering regenerative medicine as a potential new modality to treat diseases and is committed to supporting such research. The research collaboration with NsGene marks one of Takeda’s efforts to explore a novel biologics modality and implantable drug delivery system that could potentially make an impact in the lives of many patients.